

DOI: 10.1002/ejoc.201201150

Diversely Substituted Imidazo[1,2-*a*]pyrazine-8-oxo-3-carbaldehydes: An Iodine-Mediated Cyclization/Oxidation Approach

Nigam M. Mishra,^[a] Dipak D. Vachhani,^[a] Sachin G. Modha,^[a] and Erik V. Van der Eycken^{*[a]}

Keywords: Synthetic methods / Nitrogen heterocycles / Iodine / Oxidation / Cyclization / Cross-coupling / Alkynes

A mild and efficient iodine-mediated intramolecular heteroannulation approach for the construction of the imidazo[1,2-a]pyrazinone core has been developed. Under ambient conditions, this metal-free protocol allows easy access to densely functionalized imidazo[1,2-a]pyrazinone-3-carbaldehydes or (aminomethyl)imidazo[1,2-a]pyrazinones from

Introduction

Imidazo[1,2-*a*]pyrazinones^[1] are a very important class of heterocyclic compounds, as many of them have been developed into, for example, GABAA agonists,^[1a,1d] antiarrhythmic agents,^[1e] and kinase modulators.^[1c] As a result, imidazo[1,2-*a*]pyrazinones have generated considerable interest in the last two decades, and different synthetic approaches have been reported. However, most of these approaches rely on long synthetic sequences^[1b,1e] and lack the possibility to generate diversity.^[1]

Metal-catalyzed^[2] intra- or intermolecular carbocyclizations^[3] and heteroannulations^[4] of alkynes have been extensively used in recent years for the construction of diversely substituted heterocycles.^[5] Although selective and highyielding, such metal-catalyzed approaches have a drawback, which is that traces of the metals must be removed after the reaction. This has inspired organic chemists to develop metal-free approaches for the synthesis of such biologically important heterocycles.^[6] Iodine activates alkynes very well, and most often, an iodo group will remain in the molecule after cyclization, allowing the introduction of additional functionalities.^[4a,7] Thus, iodine-mediated metal-free approaches are generating interest in organic chemistry.^[8] As part of our continuing research into transformations of the 3,5-dichloropyrazinone^[9,10] skeleton and the development of diversity-orientated concise routes for the synthesis of

Homepage: http://chem.kuleuven.be/organ/lomac/

substrates containing terminal alkynes by cyclization and subsequent oxidation or amination. Further diversification may be introduced by using substrates containing an internal alkyne and/or Suzuki coupling after cyclization to generate polysubstituted (dihydro)imidazo[1,2-*a*]pyrazinones.

biologically interesting heterocycles,^[3,11] we developed an iodine-mediated intramolecular heteroannulation approach for the synthesis of the imidazo[1,2-a]pyrazinone core.

Results and Discussion

Following on from our recent report on the chemoselective Ag^I- and Au^I-catalyzed synthesis of pyrazino[2,1-b]quinazolines and 3-indolylpyrazin-2(1H)-ones,^[4b] we envisioned that iodine may be used for this heteroannulation. To investigate this idea, we synthesized starting compound 2a by treatment of readily available 3,5-dichloropyrazin-2(1H)-one^[12] 1a with propargylamine and diisopropylethylamine (DIPEA) in acetonitrile at 70 °C for 6 h (Table 1). Compound 2a was stirred with I_2 (3 equiv.) in CH_2Cl_2 at room temp. TLC and MS analysis indicated that 2a was entirely consumed after 12 h. Surprisingly, MS and NMR spectroscopic analysis of the purified product showed that aldehyde^[7a,7b,13] **3a** had been formed (Table 1, entry 1), whereas MS analysis during the reaction had shown the presence of iodine-containing compound 3a', as well as the corresponding hydrolyzed compound (i.e., 3a''). We concluded that oxidation of this primary alcohol (i.e., 3a'') to aldehyde 3a due to the presence of air during the reaction and column chromatography must have occured. Further optimization of the conditions was required to exploit the tendency of this alcohol to be oxidized. To our satisfaction, the yield of 3a increased dramatically to 80%, when hydrogen peroxide (50% in water, 8.0 mmol) was added after complete consumption of 2a (Table 1, entry 2). Importantly, the amount of iodine could be decreased to 2 equiv. without a significant drop in the yield. However a further decrease seemed to be deleterious for the reaction (Table 1, entries 3

 [[]a] Laboratory for Organic & Microwave-Assisted Chemistry (LOMAC), Department of Chemistry, KU Leuven, Celestijnenlaan 200F, Heverlee 3001, Leuven, Belgium Fax: +32-16-327-990
 E-mail: erik.vandereycken@chem.kuleuven.be

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/ejoc.201201150.

and 4). To further enhance the reaction performance, different solvents were evaluated, and THF was found to be the best solvent (Table 1, entries 5–7). Using iodine monochloride (ICl) or *N*-iodosuccinimide (NIS) as the iodine source resulted in lower yields (Table 1, entries 8 and 9). Finally, of the different oxidants examined, H_2O_2 was found to be the best (Table 1, entries 10, 12, and 13). The amount of oxidant could be decreased from 8.0 mmol to 5.0 mmol without compromising the yield (Table 1, entries 10 and 11).

Table 1. Optimization of the iodine-mediated intramolecular heteroannulation. $^{[a]}$



Entry	Solvent	Iodine source (equiv.)	Oxidant	Yield ^[b] of 3a [%]
1	CH ₂ Cl ₂	I ₂ (3)	_	30
2	CH ₂ Cl ₂	$I_{2}(3)$	H ₂ O ₂ (8.0 mmol)	80
3	CH_2Cl_2	$I_{2}(2)$	H ₂ O ₂ (8.0 mmol) ^[c]	75
4	CH ₂ Cl ₂	$I_{2}(1.5)$	H_2O_2 (8.0 mmol)	45
5	MeČN	$I_{2}(2)$	H_2O_2 (8.0 mmol)	95
6	acetone	$I_2(2)$	H_2O_2 (8.0 mmol)	50
7	THF	$I_{2}(2)$	H_2O_2 (8.0 mmol)	99
8	THF	ICl (2)	H_2O_2 (8.0 mmol)	65
9	THF	NIS (2) ^[d]	H_2O_2 (8.0 mmol)	74
10	THF	$I_2(2)$	H_2O_2 (5.0 mmol)	99
11	THF	$I_2(2)$	H_2O_2 (3.0 mmol)	80
12	THF	$I_{2}(2)$	aq. $K_2Cr_2O_3$ (2 equiv.)	50
13	THF	$I_{2}(2)$	aq. mCPBA (2 equiv.)	57

[a] All reactions were carried out with **2a** (0.3 mmol) in the indicated solvent (5 mL) at room temp. for 12 h. Then the oxidant was added, and the mixture was stirred for 2–4 h. [b] Isolated yields. [c] H_2O_2 (50% in water). [d] NIS = *N*-Iodosuccinimide.

With the optimum conditions established (Table 1, entry 10), the scope of this newly developed process was evaluated. A set of diversely substituted propynylaminopyrazinones **2b**-i was synthesized from the corresponding 3,5-dichloropyrazin-2(1*H*)-ones (i.e., **1b**-i), and was subjected to the reaction conditions. In most cases, complete conversion was obtained in 12–14 h at room temp., yielding imidazo[1,2-*a*]pyrazinone-3-carbaldehydes **3b**-i in good to excellent yields, regardless of the substitution pattern of the pyrazinone (Table 2).

Table 2. One-pot sequential cyclization/oxidation approach towards imidazo[1,2-*a*]pyrazinone-3-carbaldehyde.^[a]

	$ \begin{array}{c} $	i) I ₂ (2 eq ii) H ₂ O ₂ 5.0 m	(50% in H ₂ O, THF, r.t.	
Entry	Product	\mathbb{R}^1	R ²	Yield ^[b] [%]
1	3a	PMP	Н	99
2	3b	Ph	Me	72
3	3c	Me	Me	72
4	3d	Me	Ph	72
5	3e	Bn	Н	80
6	3f	PMB	Н	72
7	3g	PMP	PMP	88
8	3h	Ph	$2-MeOC_6H_4$	99
9	3i	PMB	PMP	74

[a] Conditions: **2** (0.3 mmol) and I₂ (2 equiv.) in THF, room temp., 12–14 h, then H_2O_2 (50% in water, 5.0 mmol), room temp., 2–4 h. [b] Isolated yields.

To further evaluate the utility of the protocol on alkynesubstituted propynylaminopyrazinones, substrates **5a–c** were synthesized by Sonogashira coupling of **2a,b** with the aryl iodides iodobenzene (**4a**) and 1-iodo-4-methoxybenzene (**4b**) by treatment with Pd(PPh_3)₂Cl₂ (2 mol-%) and CuI (3 mol-%) in a mixture of Et₃N/DMSO (3:1) at 40 °C for 1 h. When the resulting (arylpropynylamino)pyrazinones **5a–c** were subjected to the reaction conditions, the iodine-mediated heteroannulation proceeded very well, and we were able to isolate the 3-iodomethylene 2,3-dihydroimidazo[1,2-*a*]pyrazin-8(7*H*)-ones **6a–c** containing an (*E*)configured exocyclic double bond (Table 3).^[14] However, upon addition of an oxidant, these compounds decomposed completely.

Table 3. Iodine-mediated heteroannulation of (arylpropynylamino)-pyrazinones ${\bf 5a-c.}^{[a]}$

	R ¹ CI N N N 5a−c	R	l₂ (2 equiv.) THF, r.t.		
Entry	Product	\mathbb{R}^1	\mathbb{R}^2	R	Yield ^[b] [%]
1 2 3	6a 6b 6c	PMP Ph PMP	H CH ₃ H	H H OCH ₃	68 48 91

[a] Conditions: 5 (0.3 mmol) and I_2 (2 equiv.) in THF, room temp., 12–15 h. [b] Isolated yields.

On the basis of literature reports^[7] and our experimental observations, a plausible mechanism for the iodine-mediated heteroannulation is shown in Scheme 1. Nucleophilic attack of nitrogen on the activated alkyne generates intermediate A, which, after deprotonation and subsequent isomerization of the double bond, produces B. This intermediate produces the final carbaldehydes (i.e., 3) by hydrolysis and subsequent oxidation. However, in case of an internal alkyne 5, deprotonation of intermediate A results in 6, without further hydrolysis.



Scheme 1. Plausible mechanism for the iodine-mediated regioselective 5-exo-dig heteroannulation of propynylaminopyrazinones.

Next, we became interested in using highly reactive intermediate **B** to generate amino-substituted imidazo[1,2-*a*]pyrazinones. To our delight, when the reaction mixture was treated with an excess (3 equiv.) of cyclic secondary amines after the cyclization step was complete, the reaction worked well and amino-substituted products **8a–c** were formed (Table 4). However, only traces of product or even no reaction was observed when the reaction was attempted with an acyclic secondary amine (i.e, diisobutylamine) or a primary amine (i.e., benzylamine).

Finally, to further decorate the synthesized imidazo[1,2a]pyrazin-3-carbaldehydes **3a,b,e**, the 5-Cl group was used as a convenient synthetic handle. It is worth mentioning that such a Suzuki coupling could not be performed before the heteroannulation had been done.^[15] Using imidazopyrazinone **3** (1 equiv.), boronic acid **9** (1.5 equiv.), Pd(OAc)₂ (5 mol-%), S-Phos (10 mol-%), and K₂CO₃ (2 equiv.) in THF/water (7:3) at 110 °C for 30 min under microwave irradiation, we could generate further diversity at the 5-position (Table 5). This newly developed protocol allowed the installation of diverse substituents on both the 5- and 6-positions of the imidazo-pyrazinone, which is rather difficult to achieve otherwise.^[1] However, when compound **6c** was subjected to Suzuki coupling, diarylated product **11** was isolated in 65% yield as the sole product (Scheme 2).



[a] Conditions: **2a** (0.3 mmol) and I_2 (3 equiv.) in CH₂Cl₂, room temp., 12–15 h, then amine **7** (3 equiv.), room temp., 3–5 h. Isolated yields.

Table 5. Synthesis of polysubstituted imidazo [1,2-a]pyrazin-3-carbaldehydes.^[a]



[a] Isolated yield. [b] **3** (0.3 mmol), boronic acid **9** (1.5 equiv.), Pd(OAc)₂ (5 mol-%), S-Phos (10 mmol-%) and K_2CO_3 (2 equiv.) in THF/water (7:3; 2 mL), 110 °C, 30 min.



Table 4. One-pot sequential cyclization/amination approach towards aminomethyl-imidazo[1,2-*a*]pyrazinone.^[a]



Scheme 2. Synthesis of polysubstituted dihydroimidazo[1,2-*a*]-pyrazinone **11**.

Conclusions

In summary, we have developed an efficient and mild iodine-mediated approach for the synthesis of (dihydro)imidazo[1,2-*a*]pyrazinones using a 5-*exo-dig* intramolecular heteroannulation strategy. For terminal alkynes, a hydrolysis and oxidation sequence or an amination gives direct access to imidazo[1,2-*a*]pyrazinone-3-carbaldehydes or aminomethylimidazo[1,2-*a*]pyrazinones in a one-pot process. Mild reaction conditions, good to excellent yields, and tolerance of a range of substituents are merits of this protocol. Moreover, the above approach also allowed convenient access to polysubstituted (dihydro)imidazo[1,2-*a*]pyrazinones by Suzuki coupling.

Experimental Section

General Remarks: ¹H and ¹³C NMR spectra were recorded with a Bruker Avance 300 MHz instrument using CDCl₃ or [D₆]DMSO as solvent unless otherwise stated. The ¹H and ¹³C NMR chemical shifts are reported in parts per million (ppm) relative to tetramethylsilane using the residual solvent signal as an internal reference. Mass spectra were recorded using a Kratos MS50TC and a Kratos Mach III system. The ion source temperature was 150–250 °C, as required. High-resolution electron impact (EI) mass spectra were performed with a resolution of 10000. The low-resolution spectra were obtained with a HP5989A MS instrument. For TLC, analytical TLC plates (Alu-gram SIL G/UV254) and 70–230 mesh silica gel (E. M. Merck) were used.

Microwave Irradiation Experiments: All microwave irradiation experiments were carried out in a dedicated CEM-Discover monomode microwave apparatus, operating at a frequency of 2.45 GHz with continuous irradiation with a maximum power of 300 W. The reactions were carried out in 10 mL glass vials sealed with a Teflon[®] septum and placed in the microwave cavity. Initially, the temperature was raised to the desired reaction temperature. Once this temperature for the required time. The reaction mixture was magnetically stirred continuously during the reaction. The temperature was measured with an IR sensor on the outer surface of the vial. After the irradiation was complete, the reaction vessel was cooled rapidly to ambient temperature by an air jet.

General Procedure for the Synthesis of 3-(Prop-2-ynylamino)pyrazin-2(1*H***)-ones 2a–i:** Propargylamine (3 mmol, 1.5 equiv.) and diisopropylethylamine (DIPEA; 6 mmol, 3 equiv.) were added to a solution of substituted 3,5-dichloropyrazine-2(1*H*)-one (1) (2 mmol, 1 equiv.) in THF (25 mL). The reaction mixture was stirred at 60 °C for 6–10 h. After the reaction was complete, THF was removed under reduced pressure, and the mixture was partitioned between ethyl acetate (2×50 mL) and water (50 mL). The organic phase was separated, washed with brine, and dried with Na₂SO₄. The solvent was distilled off, and the residue was subjected to silica gel chromatography (30–60% ethyl acetate in heptane) to give compounds **2a–i**.

5-Chloro-1-(4-methoxyphenyl)-3-(prop-2-ynylamino)pyrazin-2(1*H***)one (2a): Pale yellow solid, 84% yield, m.p. 170–172 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.30 (d,** *J* **= 8.8 Hz, 2 H), 6.99 (d,** *J* **= 8.8 Hz, 2 H), 6.68 (s, 1 H), 6.52 (s, 1 H, NH), 4.26 (dd,** *J* **= 2.4, 5.5 Hz, 2 H, CH₂), 3.85 (s, 3 H), 2.28 (s, 1 H, alkyne-CH) ppm. ¹³C NMR (75 MHz, CDCl₃): \delta = 154.4, 144.8, 144.5, 126.4, 121.5, 121.3, 109.4, 109.1, 73.7, 66.7, 50.3, 25.6 ppm. HRMS (EI): calcd. for C₁₄H₁₂ClN₃O₂ 289.0618; found 289.0591.**

5-Chloro-6-methyl-1-phenyl-3-(prop-2-ynylamino)pyrazin-2(1*H***)one (2b): Pale yellow solid, 66% yield, m.p. 165–167 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.56–7.48 (m, 3 H), 7.17 (d,** *J* **= 6.5 Hz, 2 H), 6.29 (s, 1 H, NH), 4.23 (dd,** *J* **= 2.4, 5.3 Hz, 2 H, CH₂), 2.25 (t,** *J* **= 2.49 Hz, 1 H, alkyne-CH), 1.93 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): \delta = 151.4, 147.8, 137.3, 129.9, 129.4, 127.4, 125.0, 120.5, 79.3, 71.6, 30.6, 16.9 ppm. HRMS (EI): calcd. for C₁₄H₁₂CIN₃O 273.0668; found 273.0662.**

5-Chloro-1,6-dimethyl-3-(prop-2-ynylamino)pyrazin-2(1*H***)-one (2c):** White solid, 30% yield, m.p. 151–153 °C. ¹H NMR (300 MHz, CDCl₃): δ = 6.25 (s, 1 H, NH), 4.19 (dd, *J* = 2.4, 5.5 Hz, 2 H, CH₂), 3.53 (s, 3 H), 2.35 (s, 3 H), 2.25 (t, *J* = 2.4 Hz, 1 H, alkyne-CH) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 151.3, 147.1, 125.0, 120.5, 79.4, 71.6, 32.0, 30.6, 15.9 ppm. HRMS (EI): calcd. for C₉H₁₀ClN₃O 211.0512; found 211.0514.

5-Chloro-1-methyl-6-phenyl-3-(prop-2-ynylamino)pyrazin-2(1*H***)one (2d): Yellow solid, 90 % yield, m.p. 119–121 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.60–7.45 (m, 3 H), 7.33–7.28 (m, 2 H), 6.41 (br. s, 1 H, NH), 4.27 (dd,** *J* **= 2.5, 5.5 Hz, 2 H, CH₂), 3.22 (s, 3 H), 2.28 (t,** *J* **= 2.3 Hz, 1 H, alkyne-CH) ppm. ¹³C NMR (75 MHz, CDCl₃): \delta = 151.0, 148.2, 132.2, 130.2, 129.4, 129.0, 125.7, 124.8, 79.2, 71.8, 34.2, 30.7 ppm. HRMS (EI): calcd. for C₁₄H₁₂ClN₃O 273.0669; found 273.0680.**

1-Benzyl-5-chloro-3-(prop-2-ynylamino)pyrazin-2(1*H***)-one (2e): Offwhite solid, 80% yield, m.p. 170–172 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.37–7.32 (m, 3 H), 7.31–7.27 (m, 2 H), 6.53–6.50 (m, 2 H, NH, Ar), 5.01 (s, 2 H, CH₂Ar), 4.21 (dd,** *J* **= 2.4, 5.4 Hz, 2 H, CH₂NH), 2.26 (t,** *J* **= 2.4 Hz, 1 H, alkyne-CH) ppm. ¹³C NMR (75 MHz, CDCl₃): \delta = 150.1, 149.5, 134.7, 129.0, 128.6, 128.3, 126.7, 112.9, 78.9, 72.0, 51.8, 30.8 ppm. HRMS (EI): calcd. for C₁₄H₁₂ClN₃O 273.0668; found 273.0668.**

5-Chloro-1-(4-methoxybenzyl)-3-(prop-2-ynylamino)pyrazin-2(1*H***)one (2f): Pale yellow solid, 85% yield, m.p. 197–199 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.24 (d,** *J* **= 8.4 Hz, 2 H), 6.88 (d,** *J* **= 8.4 Hz, 2 H), 6.52 (s, 1 H), 6.44 (br. s, 1 H, NH), 4.94 (s, 2 H, CH₂Ar), 4.21 (dd,** *J* **= 2.4, 5.4 Hz, 2 H, CH₂NH), 3.80 (s, 3 H), 2.26 (s, 1 H, alkyne-CH) ppm. . ¹³C NMR (100 MHz, [D₆]DMSO): \delta = 159.7, 150.2, 150.1, 130.1, 128.5, 125.3, 114.7, 113.9, 81.1, 72.9, 55.7, 51.0, 30.3 ppm. HRMS (EI): calcd. for C₁₅H₁₄ClN₃O₂ 303.0774; found 303.0771.**

5-Chloro-1,6-bis(4-methoxyphenyl)-3-(prop-2-ynylamino)pyrazin-2(1*H***)-one (2g): Yellow solid, 88% yield, m.p. 137–139 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 6.98 (d,** *J* **= 8.6 Hz, 2 H), 6.87 (d,** *J* **= 8.7 Hz, 2 H), 6.75–6.67 (m, 4 H), 6.50 (t,** *J* **= 5.4 Hz, 1 H, NH), 4.29 (dd,** *J* **= 2.4, 5.6 Hz, 2 H, CH₂), 3.72 (s, 6 H), 2.28 (t,** *J* **=** 2.4 Hz, 1 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 159.2, 159.0, 151.3, 148.6, 132.2, 130.0, 129.1, 126.0, 125.1, 124.5, 114.2, 113.4, 79.3, 71.7, 55.3, 55.1, 30.71 ppm. HRMS (EI): calcd. for C₂₁H₁₈ClN₃O₃ 395.1036; found 395.1030.

5-Chloro-6-(2-methoxyphenyl)-1-phenyl-3-(prop-2-ynylamino)pyrazin-2(1*H***)-one (2h): Yellow solid, 78% yield, m.p. 223–225 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.28–7.11 (m, 5 H), 7.09 (d,** *J* **= 1.8 Hz, 1 H), 7.07 (d,** *J* **= 1.7 Hz, 1 H), 6.90 (d,** *J* **= 4.7 Hz, 1 H), 6.61 (d,** *J* **= 8.2 Hz, 1 H), 6.49 (br. s, 1 H, NH), 4.31 (dd,** *J* **= 2.4, 5.6 Hz, 2 H, CH₂), 3.64 (s, 3 H), 2.29 (t,** *J* **= 2.4 Hz, 1 H, alkyne-CH) ppm. ¹³C NMR (75 MHz, CDCl₃): \delta = 156.7, 151.0, 148.8, 137.2, 132.5, 130.8, 128.5, 128.3, 128.2, 127.9, 127.5, 126.2, 122.1, 121.1, 120.1, 110.5, 79.3, 71.8, 55.0, 30.7 ppm. HRMS (EI): calcd. for C₂₁H₁₈ClN₃O₂ 365.0931; found 365.0875.**

5-Chloro-1-(4-methoxybenzyl)-6-(4-methoxyphenyl)-3-(prop-2-ynyl-amino)pyrazin-2(1*H***)-one (2i): Yellow solid, 35% yield, m.p. 113–115 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.01 (d,** *J* **= 8.6 Hz, 2 H), 6.89 (d,** *J* **= 8.6 Hz, 2 H), 6.74 (m, 4 H), 6.50 (t,** *J* **= 5.5 Hz, 1 H, NH), 4.94 (s, 2 H, CH₂Ar), 4.26 (dd,** *J* **= 2.4, 5.4 Hz, 2 H, CH₂NH), 3.84 (s, 3 H), 3.75 (s, 3 H), 2.28 (t,** *J* **= 2.3 Hz, 1 H, alkyne-CH) ppm. ¹³C NMR (75 MHz, CDCl₃): \delta = 160.1, 159.0, 151.1, 148.6, 132.1, 128.8, 127.8, 126.6, 124.4, 124.0, 113.9, 113.7, 79.2, 71.9, 55.3, 55.2, 48.8 ppm. HRMS (EI): calcd. for C₂₂H₂₀ClN₃O₃ 409.1193; found 409.1200.**

General Procedure for the Synthesis of Imidazo[1,2-a]pyrazinone-3carbaldehydes 3a-i: Compound 2 (0.3 mmol, 1 equiv.) was dissolved in THF (5 mL) in a 25 mL round-bottomed flask fitted with a condenser, and iodine (0.6 mmol, 2 equiv.) was added. The mixture was stirred at room temp. for 12–14 h. After complete consumption of 2, H₂O₂ (50% in H₂O, 5.0 mmol) was added, and stirring was continued for 2–4 h at room temp. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. Na₂S₂O₃ (satd. aq., 25 mL) was added to the resulting crude material, and the mixture was extracted with ethyl acetate (2×25 mL). The organic extracts were washed with water (25 mL) and brine (25 mL), and dried with Na₂SO₄. The solvent was distilled off, and the residue was subjected to silica gel chromatography (50–70% ethyl acetate in heptane) to give compounds 3a–i.

5-Chloro-7-(4-methoxyphenyl)-8-oxo-7,8-dihydroimidazo[1,2-*a***]-pyrazine-3-carbaldehyde (3a):** Yellow solid, 99% yield, m.p. 263– 265 °C. ¹H NMR (300 MHz, [D₆]DMSO): δ = 10.63 (s, 1 H), 8.28 (s, 1 H), 7.83 (s, 1 H), 7.48 (d, *J* = 8.1 Hz, 2 H), 7.14 (d, *J* = 8.1 Hz, 2 H), 3.88 (s, 3 H) ppm. ¹³C NMR (75 MHz, [D₆]DMSO): δ = 180.4, 159.0, 151.6, 140.4, 138.8, 131.4, 131.2, 127.9, 121.9, 114.2, 108.2, 55.4 ppm. HRMS (EI): calcd. for C₁₄H₁₀ClN₃O₃ 303.0410; found 303.0409.

5-Chloro-6-methyl-8-oxo-7-phenyl-7,8-dihydroimidazo[1,2-*a***]-pyrazine-3-carbaldehyde (3b):** Yellow solid, 86% yield, m.p. 211– 213 °C. ¹H NMR (300 MHz, CDCl₃): δ = 10.69 (s, 1 H), 8.26 (s, 1 H), 7.60–7.52 (m, 3 H), 7.27–7.23 (m, 2 H), 2.13 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 179.8, 152.7, 140.2, 139.8, 136.7, 132.0, 130.1, 129.8, 128.1, 127.8, 107.6, 17.9 ppm. HRMS (EI): calcd. for C₁₄H₁₀ClN₃O₂ 287.0461; found 287.0481.

5-Chloro-6,7-dimethyl-8-oxo-7,8-dihydroimidazo[1,2-*a***]pyrazine-3carbaldehyde (3c):** Yellow solid, 72% yield, m.p. 241–243 °C. ¹H NMR (300 MHz, CDCl₃): δ = 10.64 (s, 1 H), 8.23 (s, 1 H), 3.66 (s, 3 H), 2.56 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 179.7, 152.9, 140.2, 139.4, 131.8, 127.7, 107.4, 31.9, 16.7 ppm. HRMS (EI): calcd. for C₉H₈ClN₃O₂ 225.0305; found 225.0306.

5-Chloro-7-methyl-8-oxo-6-phenyl-7,8-dihydroimidazo[1,2-*a***]-pyrazine-3-carbaldehyde (3d):** Yellow solid, 82% yield, m.p. 311–



313 °C. ¹H NMR (300 MHz, CDCl₃): δ = 10.63 (s, 1 H), 8.28 (s, 1 H), 7.65–7.55 (m, 3 H), 7.40 (t, *J* = 7.31 Hz, 2 H), 3.29 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 179.6, 152.8, 140.3, 139.8, 132.0, 131.8, 130.8, 130.6, 129.6, 129.4, 108.7, 34.2 ppm. HRMS (EI): calcd. for C₁₄H₁₀ClN₃O₂ 287.0461; found 287.0460.

7-Benzyl-5-chloro-8-oxo-7,8-dihydroimidazo[1,2-*a***]pyrazine-3-carbaldehyde (3e):** Yellow solid, 80% yield, m.p. 181–183 °C. ¹H NMR (300 MHz, CDCl₃): δ = 10.60 (s, 1 H), 8.24 (s, 1 H), 7.45–7.32 (s, 5 H), 6.92 (s, 1 H), 5.19 (s, 2 H, CH₂Ar) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 179.0, 152.0, 140.4, 140.2, 134.6, 131.8, 129.2, 128.9, 128.5, 119.6, 109.2, 51.0 ppm. HRMS (EI): calcd. for C₁₄H₁₀ClN₃O₂ 287.0461; found 287.0460.

5-Chloro-7-(4-methoxybenzyl)-8-oxo-7,8-dihydroimidazo[1,2-*a***]-pyrazine-3-carbaldehyde (3f):** Yellow solid, 72% yield, m.p. 188– 190 °C. ¹H NMR (300 MHz, CDCl₃): δ = 10.60 (s, 1 H), 8.26 (s, 1 H), 7.31 (d, *J* = 8.6 Hz, 2 H), 6.91 (d, *J* = 8.6 Hz, 2 H), 6.85 (s, 1 H), 5.12 (s, 2 H, CH₂Ar), 3.81 (s, 3 H) ppm. ¹³C NMR (75 MHz, [D₆]DMSO): δ = 180.4, 158.9, 151.5, 138.6, 129.5, 128.1, 120.9, 113.9, 108.3, 55.0, 49.8 ppm. HRMS (EI): calcd. for C₁₅H₁₁ClN₂O₃ 317.0567; found 317.0607.

5-Chloro-6,7-bis(4-methoxyphenyl)-8-oxo-7,8-dihydroimidazo[1,2-*a***]-pyrazine-3-carbaldehyde (3g):** Yellow solid, 94% yield, m.p. 228– 230 °C. ¹H NMR (300 MHz, CDCl₃): δ = 10.68 (s, 1 H), 8.30 (s, 1 H), 7.08 (d, *J* = 8.6 Hz, 2 H), 6.96 (d, *J* = 8.8 Hz, 2 H), 6.76 (t, *J* = 8.8 Hz, 4 H), 3.77 (s, 3 H), 3.73 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 179.8, 160.1, 159.2 152.9, 140.3, 140.2, 132.3, 132.2, 131.7, 129.8, 129.3, 122.9, 114.3, 113.9, 108.9, 55.3, 55.2 ppm. HRMS (EI): calcd. for C₂₂H₁₇ClN₃O₄ 409.0825; found 409.0829.

5-Chloro-6-(2-methoxyphenyl)-8-oxo-7-phenyl-7,8-dihydroimidazo-[1,2-*a*]pyrazine-3-carbaldehyde (3h): Yellow solid, 99% yield, m.p. > 320 °C. ¹H NMR (300 MHz, CDCl₃): δ = 10.71 (s, 1 H), 8.33 (s, 1 H), 7.30–7.15 (m, 5 H), 7.13–7.09 (m, 2 H), 6.87 (t, *J* = 7.5 Hz, 1 H), 6.71 (d, *J* = 8.2 Hz, 1 H), 3.73 (s, 3 H) ppm. ¹³C NMR (100 MHz, [D₆]DMSO): δ = 183.1, 159.0, 154.9, 142.8, 141.9, 139.7, 134.7, 134.5, 134.3, 131.6, 131.2, 131.1, 130.8, 122.9, 122.6, 114.0, 111.2, 58.1 ppm. HRMS (EI): calcd. for C₂₁H₁₅ClN₃O₃ 379.0723; found 379.0717.

5-Chloro-7-(4-methoxybenzyl)-6-(4-methoxyphenyl)-8-oxo-7,8-di-hydroimidazo[1,2-*a***]pyrazine-3-carbaldehyde (3i):** Yellow solid, 74% yield, m.p. 185–187 °C. ¹H NMR (300 MHz, CDCl₃): δ = 10.61 (s, 1 H), 8.29 (s, 1 H), 7.06 (d, *J* = 8.6 Hz, 2 H), 6.97 (d, *J* = 8.6 Hz, 2 H), 6.78 (d, *J* = 8.6 Hz, 2 H), 6.69 (d, *J* = 8.6 Hz, 2 H), 5.06 (s, 2 H, CH₂Ar), 3.89 (s, 3 H), 3.74 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 179.7, 160.9, 159.2, 153.1, 140.3, 140.1, 132.1, 131.6, 131.5, 129.1, 127.9, 122.4, 114.4, 113.7, 109.4, 55.4, 55.2, 48.4 ppm. HRMS (EI): calcd. for C₂₂H₁₈ClN₃O₄ 423.0985; found 423.0972.

General Procedure for the Synthesis of Compounds 5a–c: Compound 2 (0.7 mmol, 1 equiv.), aryl iodide 4 (0.77 mmol, 1.1 equiv.), Pd(PPh₃)₂Cl₂ (2 mol-%), and CuI (3 mol-%) were added to an oven-dried 25 mL two-necked flask equipped with a stirrer-bar under argon. The flask was evacuated and refilled with argon (3 ×). Dry Et₃N/DMSO (4:1; 10 mL) were added by syringe, and the resulting suspension was allowed to stir at 45 °C for 1 h. After completion of reaction, as indicated by TLC and MS analysis, the mixture was cooled to room temperature. The crude mixture was diluted with ethyl acetate (50 mL), and washed with H₂O (50 mL). The organic phase was washed with brine (50 mL), and dried with anhydrous Na₂SO₄. The solvent was removed under reduced pressure, and the crude sample was purified by silica gel column chromatography (35–40% ethyl acetate in heptane) to give compounds **5a–c**.

5-Chloro-1-(4-methoxyphenyl)-3-(3-phenylprop-2-ynylamino)pyrazin-2(1*H***)-one (5a): Yellow solid, 72% yield, m.p. 95 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.45–7.39 (m, 2 H), 7.35–7.27 (m, 5 H), 6.98 (d,** *J* **= 8.5 Hz, 2 H), 6.66–6.63 (m, 2 H, Ar, NH), 4.27 (d,** *J* **= 5.5 Hz, 2 H, CH₂), 3.83 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): \delta = 159.7, 150.2, 149.7, 131.7, 128.4, 128.3, 126.8, 126.7, 122.5, 114.66, 114.1, 84.2, 83.7, 55.6, 31.7 ppm. HRMS (EI): calcd. for C₂₀H₁₆N₃O₂ 365.0931; found 365.0930.**

5-Chloro-6-methyl-1-phenyl-3-(3-phenylprop-2-ynylamino)pyrazin-2(1*H***)-one (5b): Yellow solid, 80% yield, m.p. 128–130 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.56–7.48 (m, 3 H), 7.47–7.41 (m, 2 H), 7.31–7.28 (m, 3 H), 7.17 (d,** *J* **= 6.7 Hz, 2 H), 6.35 (br. s, 1 H, NH), 4.46 (d,** *J* **= 5.2 Hz, 2 H, CH₂), 1.93 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): \delta = 151.5, 147.8, 137.4, 131.7, 129.9, 129.3, 128.3, 128.2, 127.4, 125.1, 122.6, 120.3, 84.6, 83.5, 31.5, 16.9 ppm. HRMS (EI): calcd. for C₂₀H₁₆ClN₃O 349.0982; found 349.0961.**

5-Chloro-1-(4-methoxyphenyl)-3-[3-(4-methoxyphenyl)prop-2-ynylamino]pyrazin-2(1*H***)-one (5c): Yellow solid, 84% yield, m.p. 130– 132 °C. ¹H NMR (300 MHz, CDCl₃): \delta = 7.37 (d,** *J* **= 8.8 Hz, 2 H), 7.30 (d,** *J* **= 9.0 Hz, 2 H), 6.98 (d,** *J* **= 9 Hz, 2 H), 6.82 (d,** *J* **= 8.6 Hz, 2 H), 6.66–6.61 (m, 2 H, NH, Ar), 4.45 (d,** *J* **= 5.4 Hz, 2 H, CH₂), 3.83 (s, 3 H), 3.79 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): \delta = 159.7, 159.6, 150.1, 149.7, 133.2, 131.7, 126.8, 126.6, 114.6, 114.5, 114.0, 113.9, 83.7, 82.8, 55.5, 55.2, 31.8 ppm. HRMS (EI): calcd. for C₂₁H₁₈ClN₃O₃ 395.1036; found 395.1023.**

General Procedure for the Synthesis of Dihydroimidazo[1,2-*a*]pyrazinones 6a–c: Compound 5 (0.3 mmol, 1 equiv.) was dissolved in THF (5 mL) in a 25 mL round-bottomed flask fitted with a condenser, and iodine (0.6 mmol, 2 equiv.) was added. The mixture was stirred at room temp. for 12–15 h. After complete consumption of 5, the reaction mixture was concentrated under reduced pressure. Na₂S₂O₃ (satd. aq., 25 mL) was added to the resulting crude material, and the mixture was extracted with ethyl acetate (2×25 mL). The organic phase was washed with water (25 mL) and brine (25 mL), and dried with Na₂SO₄. The solvent was distilled off, and the residue was subjected to silica gel chromatography (60-70%ethyl acetate in heptane) to give compounds **6a–c**.

(*E*)-5-Chloro-3-[iodo(phenyl)methylene]-7-(4-methoxyphenyl)-2,3-dihydroimidazo[1,2-*a*]pyrazin-8(7*H*)-one (6a): Yellow solid, 68 % yield, m.p. 122–124 °C. ¹H NMR (300 MHz, CDCl₃): δ = 7.44–7.42 (m, 3 H), 7.34–7.31 (m, 4 H), 6.98 (d, *J* = 9 Hz, 2 H), 6.09 (s, 1 H), 4.75 (s, 2 H, CH₂), 3.84 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 159.3, 155.2, 146.0, 138.3, 134.8, 131.5, 129.6, 129.3, 128.5, 126.9, 114.7, 113.8, 112.8, 73.6, 59.8, 55.5 ppm. HRMS (EI): calcd. for C₂₀H₁₅ClIN₃O₂ 490.9897; found 490.9879.

(*E*)-5-Chloro-3-[iodo(phenyl)methylene]-6-methyl-7-phenyl-2,3-dihydroimidazo[1,2-*a*]pyrazin-8(7*H*)-one (6b): Yellow solid, 48% yield, m.p. 175–177 °C. ¹H NMR (300 MHz, CDCl₃): δ = 7.53–7.42 (m, 7 H), 7.33–7.31 (m, 2 H), 7.24 (s, 1 H), 4.72 (s, 2 H, CH₂), 1.68 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 156.5, 146.0, 138.8, 136.9, 134.9, 130.0, 129.6, 129.2, 129.0, 128.4, 128.1, 118.6, 112.2, 72.7, 59.9, 16.5 ppm. HRMS (EI): calcd. for C₂₀H₁₅ClIN₃O 474.9948; found 474.9966.

(*E*)-5-Chloro-3-[iodo(4-methoxyphenyl)methylene]-7-(4-methoxyphenyl)-2,3-dihydroimidazo[1,2-*a*]pyrazin-8(7*H*)-one (6c): Yellow solid, 91% yield, m.p. 188–190 °C. ¹H NMR (300 MHz, CDCl₃): δ = 7.32 (d, *J* = 9 Hz, 2 H), 7.24 (d, *J* = 8.6 Hz, 2 H), 6.96 (t, *J* = 8.4 Hz, 4 H), 6.09 (s, 1 H), 4.72 (s, 2 H, CH₂), 3.85 (s, 3 H), 3.83 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 160.2, 159.3, 155.3, 145.9, 138.1, 131.6, 130.9, 126.99, 126.90, 114.7, 113.9, 113.8, 112.7, 72.4, 59.8, 55.5, 55.3 ppm. HRMS (EI): calcd. for C₂₁H₁₇ClIN₃O₃ 521.0003; found 521.0021.

General Procedure for the Synthesis of 3-Aminomethylimidazo[1,2a]pyrazinones 8a–c: Compound 2 (0.3 mmol, 1 equiv.) was dissolved in CH_2Cl_2 (5 mL) in a 25 mL round-bottomed flask fitted with a condenser, and iodine (0.9 mmol, 3 equiv.) was added. The mixture was stirred at room temp. for 12–15 h. After complete consumption of 2, amine (0.9 mmol, 3 equiv.) was added, and the mixture was stirred for 3–5 h at room temp. After completion of the reaction, the mixture was diluted with CH_2Cl_2 (25 mL) and washed with $Na_2S_2O_3$ (satd. aq., 25 mL). The organic phase was washed with brine and dried with Na_2SO_4 . The solvent was distilled off, and the residue was purified by silica gel chromatography (2–4% methanol in CH_2Cl_2) to give pure product 8a–c.

5-Chloro-7-(4-methoxyphenyl)-3-(morpholinomethyl)imidazo-[1,2-*a*]pyrazin-8(7*H*)-one (8a): Yellow solid, 78% yield, m.p. 200–202 °C. ¹H NMR (300 MHz, CDCl₃): δ = 7.45 (s, 1 H), 7.33 (d, *J* = 8.8 Hz, 2 H), 6.98 (d, *J* = 8.8 Hz, 2 H), 6.83 (s, 1 H), 3.88 (s, 2 H, CH₂Ar), 3.84 (s, 3 H), 3.69 (t, *J* = 4.3 Hz, 4 H), 2.51 (t, *J* = 4.3 Hz, 4 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 159.5, 152.1, 139.3, 135.2, 131.4, 128.1, 127.4, 119.3, 114.7, 109.7, 66.9, 55.6, 53.2, 52.8 ppm. HRMS (EI): calcd. for C₁₈H₁₉CIN₄O₃ 374.1145; found 374.1146.

5-Chloro-7-(4-methoxyphenyl)-3-(piperidin-1-ylmethyl)imidazo-[1,2-*a***]pyrazin-8(7***H***)-one (8b):** Yellow solid, 72 % yield, m.p. 96– 98 °C. ¹H NMR (300 MHz, CDCl₃): δ = 7.44 (s, 1 H), 7.33 (d, *J* = 8.8 Hz, 2 H), 6.99 (d, *J* = 8.8 Hz, 2 H), 6.79 (s, 1 H), 3.84 (s, 3 H), 3.83 (s, 2 H, CH₂Ar), 2.49–2.40 (m, 4 H), 1.62–1.44 (m, 6 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 159.5, 152.2, 139.0, 135.0, 131.5, 129.3, 127.5, 119.1, 114.7, 109.6, 55.6, 54.3, 53.3, 25.9, 24.2 ppm. HRMS (EI): calcd. for C₁₉H₂₁ClN₄O₂ 372.1353; found 372.1360.

5-Chloro-7-(4-methoxyphenyl)-3-(pyrrolidin-1-ylmethyl)imidazo-[1,2-*a***]pyrazin-8(7***H***)-one (8c):** Yellow solid, 50% yield, m.p. 142–144 °C. ¹H NMR (300 MHz, CDCl₃): δ = 7.47 (s, 1 H), 7.32 (d, *J* = 8.8 Hz, 2 H), 6.98 (d, *J* = 8.8 Hz, 2 H), 6.80 (s, 1 H), 4.07 (s, 2 H, CH₂Ar), 3.83 (s, 3 H), 2.66–2.53 (m, 4 H), 1.84–1.77 (m, 4 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 159.5, 152.2, 138.8, 134.4, 131.5, 130.0, 127.5, 119.2, 114.7, 109.6, 55.6, 54.0, 50.4, 23.5 ppm. HRMS (EI): calcd. for C₁₈H₁₉ClN₄O₂ 358.1196; found 358.1222.

General Procedure for the Synthesis of Polysubstituted Imidazo[1,2alpyrazine-8(7H)-ones by Suzuki Coupling 10a-d: Boronic acid 9 (0.45 mmol, 1.5 equiv.), Pd(OAc)₂ (0.015 mmol, 5 mol-%), S-Phos (0.03 mmol, 10 mol-%), and K₂CO₃ (0.6 mmol, 2 equiv.) were added to a 10 mL reaction vial containing compound 3 (0.3 mmol, 1 equiv.). Then a THF/water mixture (7:3; 2 mL) was added, and the vial was sealed tightly with a Teflon[®] cap. The mixture was irradiated for 30 min at a pre-selected temperature of 110 °C, with a maximum irradiation power of 300 W. After the reaction was complete, as monitored by TLC and MS analysis, water (25 mL) was added, and the crude mixture was extracted with ethyl acetate $(2 \times 30 \text{ mL})$. The combined organic extracts were washed with brine (25 mL), and dried with Na₂SO₄. After filtration, the solvent was evaporated under reduced pressure, and the crude product was subjected to silica gel column chromatography (70-80% ethyl acetate in heptane) to give compounds 10a-d.

5-(4-Ethoxyphenyl)-7-(4-methoxyphenyl)-8-oxo-7,8-dihydroimidazo[1,2-*a***]pyrazine-3-carbaldehyde (10a):** Light yellow solid, 53% yield, m.p. 66–68 °C. ¹H NMR (300 MHz, CDCl₃): δ = 8.87 (s, 1 H), 8.19 (s, 1 H), 7.45 (d, *J* = 8.6 Hz, 2 H), 7.39 (d, *J* = 8.8 Hz, 2 H), 7.07–6.97 (m, 4 H), 6.81 (s, 1 H), 4.09 (q, *J* = 6.9 Hz, 2 H), 3.84 (s, 3 H), 1.46 (t, *J* = 6.9 Hz, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 179.2, 160.8, 159.7, 152.4, 140.6, 140.0, 131.5, 130.9, 130.8, 127.4, 122.8, 121.9, 119.6, 115.8, 114.8, 63.8, 55.6, 14.6 ppm. HRMS (EI): calcd. for C₂₂H₁₉N₃O₄ 389.1375; found 389.1375. **7-Benzyl-8-oxo-5-phenyl-7,8-dihydroimidazo**[1,2-*a*]pyrazine-3-carbaldehyde (10b): Yellow solid, 85% yield, m.p. 98–100 °C. ¹H NMR (300 MHz, CDCl₃): δ = 8.80 (s, 1 H), 8.17 (s, 1 H), 7.55–7.42 (m, 5 H), 7.41–7.30 (m, 5 H), 6.68 (s, 1 H), 5.22 (s, 2 H, CH₂Ar) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 178.7, 152.7, 140.6, 140.2, 135.2, 131.2, 130.8, 130.6, 129.9, 129.2, 129.1, 128.6, 128.5, 120.4, 120.2, 50.8 ppm. HRMS (EI): calcd. for C₂₀H₁₅N₃O₂ 329.1164; found 329.1147.

6-Methyl-8-oxo-5,7-diphenyl-7,8-dihydroimidazo[1,2-*a*]pyrazine-**3-carbaldehyde (10c):** Yellow solid, 32% yield, m.p. 240–242 °C. ¹H NMR (300 MHz, CDCl₃): δ = 8.20 (s, 1 H), 8.16 (s, 1 H), 7.66– 7.46 (m, 8 H), 7.34–7.29 (m, 2 H), 1.76 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 179.6, 153.6, 139.9, 139.8, 136.9, 132.4, 131.1, 130.9, 130.7, 130.5, 130.0, 129.4, 128.3, 127.8, 116.7, 17.8 ppm. HRMS (EI): calcd. for C₂₀H₁₅N₃O₂ 329.1164; found 329.1159.

7-(4-Methoxyphenyl)-8-oxo-5-(*p*-tolyl)-7,8-dihydroimidazo[1,2-*a*]pyrazine-3-carbaldehyde (10d): Yellow solid, 63% yield, m.p. 152– 154 °C. ¹H NMR (300 MHz, CDCl₃): δ = 8.87 (s, 1 H), 8.20 (s, 1 H), 7.45–7.32 (m, 6 H), 7.00 (d, *J* = 8.6 Hz, 2 H), 6.82 (s, 1 H), 3.84 (s, 3 H), 2.44 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 179.1, 159.7, 152.4, 141.2, 140.7, 140.1, 131.5, 130.8, 130.7, 129.1, 128.1, 127.4, 121.9, 119.8, 114.8, 55.6, 21.4 ppm. HRMS (EI): calcd. for C₂₁H₁₇N₃O₃ 359.1269; found 359.1259.

3-[bis(4-Methoxyphenyl)methylene]-5,7-bis(4-methoxyphenyl)-2,3-dihydroimidazo[1,2-a]pyrazin-8(7H)-one (11): (p-Methoxyphenyl)boronic acid (9d) (0.44 mmol, 2.2 equiv.), $Pd(PPh_3)_4$ (0.01 mmol, 5 mol-%), and Na₂CO₃ (0.4 mmol, 2 equiv.) were added to a 10 mL reaction vial containing compound 6c (0.2 mmol, 1 equiv.). Then a mixture of dioxane/water (7:3; 2 mL) was added, and the vial was sealed tightly with a Teflon® cap. The mixture was irradiated for 30 min at a pre-selected temperature of 110 °C, with maximum irradiation power of 300 W. After the reaction was complete, as monitored by TLC and MS analysis, water (25 mL) was added, and the mixture was extracted with ethyl acetate (2×30 mL). The combined organic extracts were washed with brine (25 mL), and dried with Na_2SO_4 . After filtration, the solvent was evaporated under reduced pressure, and the crude product was subjected to silica gel column chromatography (70-80% ethyl acetate in heptane) to give compound 11. Yellow solid, 65% yield, m.p. 53-55 °C. ¹H NMR (300 MHz, CDCl₃): δ = 7.42 (d, J = 9.0 Hz, 2 H), 7.0 (d, J = 9.0 Hz, 2 H), 6.90 (d, J = 2.1 Hz, 2 H), 6.87 (d, J = 2.1 Hz, 2 H), 6.6–6.5 (m, 6 H), 6.47 (d, J = 9 Hz, 2 H), 6.03 (s, 1 H), 3.84 (s, 3 H), 3.72 (s, 2 H), 3.71 (s, 3 H), 3.68 (s, 3 H), 3.67 (s, 3 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 159.1, 158.7, 158.1, 156.3, 147.8, 134.3, 132.6, 130.9, 130.7, 129.8, 127.5, 127.2, 126.9, 124.6, 116.1, 114.9, 114.6, 116.1, 113.6, 113.4, 113.1, 112.0, 55.5, 55.2, 55.1, 55.0, 52.1 ppm. HRMS (EI): calcd. for C₃₅H₃₁N₃O₅ 573.2263; found 573.2272.

Supporting Information (see footnote on the first page of this article): Copies of ¹H and ¹³C spectra of all new compounds.

Acknowledgments

The authors wish to thank the Fund for Scientific Research, Flanders, Belgium (FWO) and the Research Fund of the University of Leuven (KU Leuven) for financial support. N. M. and D. V. are grateful to the Erasmus Mundus External Cooperation Window (EMECW), Lot 13) for a doctoral scholarship. The authors thank Ir. B. Demarsin for HRMS measurements.



- a) S. G. Goodacre, D. J. Hallett, R. W. Carling, J. L. Castro, D. S. Reynolds, A. Pike, K. A. Wafford, R. Newman, J. R. Atack, L. J. Street, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1582–1385;
 b) D. D. Davey, J. Org. Chem. **1987**, *52*, 4379–4381; c) Q. Liu, D. G. Batt, G. V. Delucca, Q. Shi, A. J. Tebben, U. S. Patent US 2010/0160303 A1, **2010**; d) W. R. Carling, J. L. Castro-Pineiro, S. C. Goodacre, D. J. Hallett, L. J. Street, PCT Int. Appl. WO 2004/041826 A1, **2004**; e) B. Plouvier, D. Fedida, G. N. Beatch, D. Chou, A. Yifru, G. Jung, PCT Int. Appl. WO 2005/ 034837 A2, **2005**; f) D. D. Vachhani, S. G. Modha, A. Sharma, E. V. Van der Eycken, *Tetrahedron* **2013**, *69*, 359–365.
- [2] a) A. De Meijere, F. Diederich (Eds.), Metal-Catalyzed Cross-Coupling Reactions, 2nd ed., Wiley-VCH, Weinheim, Germany, 2004; b) E. I. Negishi, Acc. Chem. Res. 1982, 15, 340–348; c) P. Knochel, M. I. Calaza, E. Hupe, in: Metal-Catalyzed Cross-Coupling Reactions, (Eds.: A. de Meijere, F. Diederich), Wiley-VCH, Weinheim, Germany, 2004, chapter 11; d) M. Beller, C. Bolm (Eds.), Transition Metals for Organic Synthesis 2nd ed., Wiley-VCH, Weinheim, Germany, 2004; e) E. A. V. Kentchev, C. J. O'Brien, M. G. Organ, Angew. Chem. 2007, 119, 2824– 2870; Angew. Chem. Int. Ed. 2007, 46, 2768–2813.
- [3] a) P. A. Donets, K. Van Hecke, L. Van Meervelt, E. V. Van der Eycken, *Org. Lett.* 2009, *11*, 3618–3621; b) V. A. Peskov, S. Van Hove, P. A. Donets, O. P. Pereshivko, K. Van Hecke, L. Van Meervelt, E. V. Van der Eycken, *Eur. J. Org. Chem.* 2011, 1837–1840.
- [4] a) V. P. Mehta, S. G. Modha, D. Ermolat'ev, K. Van Hecke, L. Van Meervelt, E. Van der Eycken, *Aust. J. Chem.* 2009, *62*, 27–41; b) D. D. Vachhani, V. P. Mehta, S. G. Modha, K. Van Hecke, L. Van Meervelt, E. V. Van der Eycken, *Adv. Synth. Catal.* 2012, *354*, 1593–1599.
- [5] For a thematic special issue on coinage metals in organic Synthesis see: *Chem. Rev.* **2008**, *108*, 2793–3442.
- [6] a) P. T. Parvatkar, P. S. Parameswaran, S. G. Tilve, *Chem. Eur. J.* 2012, *18*, 5460–5489; b) C. Chen, S. Yang, M. Wu, *J. Org. Chem.* 2011, *76*, 10269–10274; c) A. Sniady, K. A. Wheeler, R. Dembinski, *Org. Lett.* 2005, *7*, 1769–1772; d) D. W. Knight, A. L. Redfern, J. Gilmore, *J. Chem. Soc. Perkin Trans. 1* 2001, 2874–2883; e) D. Yue, R. C. Larock, *Org. Lett.* 2004, *6*, 1037–1040.
- [7] a) S. Li, Z. Li, Y. Yuan, D. Peng, Y. Li, L. Zhang, Y. Wu, Org. Lett. 2012, 14, 1130–1133; b) D. Sucunza, A. Samadi, M. Chioua, D. B. Silva, C. Yunta, L. Infantes, M. C. Carreiras, E. Soriano, J. Marco-Contelles, Chem. Commun. 2011, 47, 5043– 5045; c) S. K. Sharma, A. K. Mandadapu, B. Kumar, B. Kundu, J. Org. Chem. 2011, 76, 6798–6805; d) M. J. Mphahlele, Molecules 2009, 14, 4814–4837; e) H. Togo, S. Iida, Synlett 2006, 2159–2175; f) F. M. da Silva, J. J. Junior, M. C. S. de Mattos, Curr. Org. Synth. 2005, 2, 393–414; g) S. Mehta, R. C. Larock, J. Org. Chem. 2010, 75, 1652–1658; h) R. Mancuso, S. Mehta, B. Gabriele, G. Salerno, W. S. Jenks, R. C. Larock, J. Org. Chem. 2010, 75, 897–901.
- [8] a) B. Alcaide, P. Almendros, G. Cabrero, R. Callejo, M. P. Ruiz, M. Arno, L. R. Domingo, *Adv. Synth. Catal.* 2010, *352*, 1688– 1700; b) W. Lee, H. Shen, W. Hu, W. Lo, C. Murali, J. K. Vandavasi, J. Wang, *Adv. Synth. Catal.* 2012, *354*, 2218; c) K. Xu, Y. Hu, S. Zhang, Z. Zha, Z. Wang, *Chem. Eur. J.* 2012, *18*, 9793–9797; d) S. Das, R. Borah, R. R. Devi, A. J. Thakur, *Synlett* 2008, *18*, 2741–2762.
- [9] For an early review, see: a) G. Hoornaert, Bull. Soc. Chim. Belg. 1994, 103, 583–589; for a recent review, see: b) V. G. Pawar, W. M. De Borggraeve, Synthesis 2006, 2799–2814; using microwave irradiation, see: c) V. P. Mehta, P. Appukkuttan, E. Van der Eycken, Curr. Org. Chem. 2011, 15, 265–283; d) E. Van der Eycken, C. O. Kappe (Eds.), Topics in Heterocyclic Chemistry, Springer, Berlin, 2006, vol. 1, p. 267; e) N. Kaval, K. Bisztrav, W. Dehaen, C. O. Kappe, E. Van der Eycken, Mol. Diversity 2003, 7, 125–134; f) N. Kaval, B. K. Singh, D. S. Erm-

olat'ev, S. Claerhout, J. Van der Eycken, E. Van der Eycken, J. Comb. Chem. 2007, 9, 446–453.

- [10] a) V. P. Mehta, A. Sharma, E. Van der Eycken, *Adv. Synth. Catal.* 2008, *350*, 2174–2178; b) V. P. Mehta, A. Sharma, E. Van der Eycken, *Org. Lett.* 2008, *10*, 1147–1150; c) V. P. Mehta, S. G. Modha, E. Van der Eycken, *J. Org. Chem.* 2009, *74*, 6870–6873; d) N. M. Mishra, V. A. Peshkov, O. P. Pereshivko, S. G. Modha, E. V. Van der Eycken, *Tetrahedron Lett.* 2012, *53*, 4676–4678.
- [11] a) S. G. Modha, D. D. Vachhani, J. Jacobs, L. Van Meervelt, E. V. Van der Eycken, *Chem. Commun.* 2012, 48, 6550–6552; b)
 S. G. Modha, A. Kumar, D. D. Vachhani, J. Jacobs, S. K. Sharma, V. S. Parmar, L. Van Meervelt, E. V. Van der Eycken, *Angew. Chem. Int. Ed.* 2012, *51*, 9572–9575; c) S. G. Modha, A. Kumar, D. D. Vachhani, S. K. Sharma, V. S. Parmar, E. V. Van der Eycken, *Chem. Commun.* 2012, *48*, 10916–10918.
- [12] a) J. Vekemans, C. Pollers-Wieërs, G. Hoornaert, J. Heterocycl. Chem. 1983, 20, 919–923; for recent microwave-assisted Synthesis see: b) J. Gising, P. Örtqvist, A. Sandström, M. Larhed, Org. Biomol. Chem. 2009, 7, 2809–2815.
- [13] I. Kim, S. G. Kim, J. Y. Kim, G. H. Lee, *Tetrahedron Lett.* 2007, 48, 8976–8981.
- [14] The geometry of the double bond was confirmed by 2D NMR spectroscopy (NOESY). For more details, see Supporting Information.
- [15] a) V. P. Mehta, A. Sharma, K. Van Hecke, L. Van Meervelt, E. Van der Eycken, J. Org. Chem. 2008, 73, 2382–2388; b) R. Azzam, W. De Borggraeve, F. Compernolle, G. Hoornaert, Tetrahedron Lett. 2004, 45, 1885–1888.

Received: August 22, 2012

Published Online: December 11, 2012